CA2459219A1 - Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer - Google Patents

Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer Download PDF

Info

Publication number
CA2459219A1
CA2459219A1 CA002459219A CA2459219A CA2459219A1 CA 2459219 A1 CA2459219 A1 CA 2459219A1 CA 002459219 A CA002459219 A CA 002459219A CA 2459219 A CA2459219 A CA 2459219A CA 2459219 A1 CA2459219 A1 CA 2459219A1
Authority
CA
Canada
Prior art keywords
cancer
protein
sequence
nucleic acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002459219A
Other languages
English (en)
Inventor
Daniel Afar
Natasha Aziz
Kurt C. Gish
Peter A. Hevezi
David H. Mack
Keith E. Wilson
Albert Zlotnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2459219A1 publication Critical patent/CA2459219A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

L'invention concerne des gènes dont l'expression est régulée positivement ou négativement dans des cancers spécifiques ; des procédés et des compositions associées pouvant servir à diagnostiquer et à traiter ces cancers ; et des procédés pouvant servir à identifier des modulateurs de cancers sélectionnés.
CA002459219A 2001-09-17 2002-09-17 Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer Abandoned CA2459219A1 (fr)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US32346901P 2001-09-17 2001-09-17
US60/323,469 2001-09-17
US32388701P 2001-09-20 2001-09-20
US60/323,887 2001-09-20
US35066601P 2001-11-13 2001-11-13
US60/350,666 2001-11-13
US35514502P 2002-02-08 2002-02-08
US35525702P 2002-02-08 2002-02-08
US60/355,145 2002-02-08
US60/355,257 2002-02-08
US37224602P 2002-04-12 2002-04-12
US60/372,246 2002-04-12
PCT/US2002/029560 WO2003025138A2 (fr) 2001-09-17 2002-09-17 Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer

Publications (1)

Publication Number Publication Date
CA2459219A1 true CA2459219A1 (fr) 2003-03-27

Family

ID=27559718

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002459219A Abandoned CA2459219A1 (fr) 2001-09-17 2002-09-17 Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer

Country Status (5)

Country Link
EP (1) EP1434881A4 (fr)
JP (1) JP2005518782A (fr)
AU (1) AU2002330039A1 (fr)
CA (1) CA2459219A1 (fr)
WO (1) WO2003025138A2 (fr)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6986201A (en) 2000-06-16 2002-01-02 Biogen Inc Renal regulatory elements and methods of use thereof
US20060035237A1 (en) 2002-08-26 2006-02-16 Markowitz Sanford D Methods and compositions for categorizing patients
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
DE60224275T2 (de) 2001-06-01 2008-12-11 Biogen Idec Ma Inc., Cambridge Moleküle und verfahren zur inhibierung der freisetzung von kim-1
WO2003027276A2 (fr) * 2001-09-24 2003-04-03 University Of Aarhus Nouvelles compositions et procedes relatifs aux lymphomes et aux leucemies
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1310552B1 (fr) 2001-11-09 2007-06-13 Proteologics, Inc. Acides nucléiques et polypeptides Posh et procédés associés
WO2003080856A2 (fr) * 2002-03-19 2003-10-02 Curagen Corporation Polypeptides therapeutiques, acides nucleiques codant pour ceux-ci et methodes d'utilisation associees
US20060088835A1 (en) * 2002-04-05 2006-04-27 Pickard Benjamin S Schizophrenia associated genes
AU2003278137A1 (en) 2002-06-20 2004-01-06 Bristol-Myers Squibb Company Identification and regulation of a g-protein coupled receptor, rai-3
GB0215224D0 (en) * 2002-07-01 2002-08-14 Inpharmatica Ltd Protein
AU2003294250A1 (en) * 2002-11-12 2004-06-03 Wyeth A novel pth responsive gene
ES2311122T3 (es) 2002-12-30 2009-02-01 Biogen Idec Ma Inc. Antagonistas de kim-1 y uso para la modulacion del sistema inmune.
JP4462964B2 (ja) * 2003-03-10 2010-05-12 第一三共株式会社 癌特異的抗原を標的とした抗体
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP1923401A3 (fr) * 2003-04-14 2008-08-20 Novartis AG Expression génétique associée avec la différenciation des ostéoblastes
WO2004099782A2 (fr) * 2003-05-05 2004-11-18 Bayer Healthcare Ag Approche diagnostique et therapeutique des maladies associees au recepteur gpr39 (gpr39) couple a une proteine g
WO2005001049A2 (fr) * 2003-06-06 2005-01-06 Diadexus, Inc. Compositions, variants d'epissage et procedes associes a des genes et proteines ovariens specifiques
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005066363A2 (fr) * 2004-01-09 2005-07-21 Medigen Biotechnology Corporation Gene mg20 specifique du cancer
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
GB0404209D0 (en) * 2004-02-25 2004-03-31 Uws Ventures Ltd Materials and methods for treatment of allergic disease
WO2005085860A2 (fr) * 2004-02-27 2005-09-15 Institut Curie Nouveaux marqueurs de proliferation en pratique clinique et leur utilisation pour le pronostic ou diagnostic du cancer
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
DE602005024537D1 (de) 2004-04-27 2010-12-16 Takeda Pharmaceutical Neuer ligand eines g-protein-konjugierten rezeptorproteins und verwendung davon
US20080166357A1 (en) * 2004-05-11 2008-07-10 Stefan Golz Diagnostics and Therapeutics for Diseases Associated with Dipeptidyl-Peptidase 6 (Dpp6)
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
MX2007000783A (es) 2004-07-20 2007-04-09 Genentech Inc Inhibidores de proteina angiopoietina tipo 4, combinaciones y su uso.
ZA200701183B (en) 2004-07-20 2008-05-28 Genentech Inc Inhibitors of angiopoietin-like 4 protein, combinations, an their use
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EP1791565B1 (fr) 2004-09-23 2016-04-20 Genentech, Inc. Anticorps et conjugues produits avec de la cysteine
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
DE602006016413D1 (de) 2005-03-02 2010-10-07 Biogen Idec Inc Kim-1-antikörper zur behandlung von th2-vermittelten erkrankungen
NZ562436A (en) * 2005-04-18 2010-01-29 Provost Fellows & Scholars Of Toll-like receptor 14 (TLR14) and use thereof
WO2007008647A2 (fr) * 2005-07-07 2007-01-18 Vanderbilt University Diagnostic et classement de gliomes a l'aide d'une approche proteomique
AU2006320654A1 (en) * 2005-11-29 2007-06-07 Yupo Ma Targeting of SALL4 for the treatment and diagnosis of proliferative disorders associated with myelodysplastic syndrome (MDS)
DK1957539T3 (da) 2005-12-08 2013-05-06 Medarex Inc Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse
AU2007254005B2 (en) 2006-02-10 2012-11-29 Genentech, Inc. Anti-FGF19 antibodies and methods using same
ES2544957T3 (es) 2006-03-21 2015-09-07 Genentech, Inc. Terapia combinada que implica antagonistas alfa5beta1
WO2008054534A2 (fr) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Systèmes de criblage utilisant le rtp801
EP2026843A4 (fr) 2006-06-09 2011-06-22 Quark Pharmaceuticals Inc Utilisations thérapeutiques d'inhibiteurs de rtp801l
US7851144B2 (en) 2006-08-18 2010-12-14 The University Of Washington Compositions and methods for detecting cancer
GB0620695D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Composition and methods for the treatment of nurdegenerative disease
GB0620705D0 (en) 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
EP1932854A1 (fr) * 2006-12-15 2008-06-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptides s'apparentant à une protéine de membrane associée à un lysosome (LAMP), ligands correspondants et leur utilisation dans le cadre de la détection et de la purification de cellules dendritiques plasmacytoïdes humaines
EP2377952A1 (fr) * 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Procédés pour le diagnostic et le traitement d'astrocytomes
CA2817054C (fr) * 2007-07-27 2017-02-28 Immatics Biotechnologies Gmbh Composition de peptides associes a des tumeurs et vaccin anti-cancer connexe
US8236307B2 (en) 2007-08-03 2012-08-07 Genentech, Inc. Humanized anti-FGF19 antagonists and methods using same
AU2008296927C1 (en) 2007-09-06 2015-08-13 Case Western Reserve University Methods for diagnosing and treating cancers
SI2200700T1 (sl) 2007-09-26 2016-04-29 Genentech, Inc. Nova protitelesa
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
EP2313435A4 (fr) 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc Protéines se liant au récepteur 3 du facteur de croissance des fibroblastes (fgfr3)
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
US20110160085A1 (en) * 2008-08-25 2011-06-30 Katherine Li Biomarkers for anti-tnf treatment in ulcreative colitis and related disorders
CN102257138B (zh) 2008-10-20 2013-06-19 大日本住友制药株式会社 肿瘤抗原肽及其用途
AU2014201027B2 (en) * 2008-12-08 2015-11-19 Compugen Ltd. FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
AU2009325878B2 (en) 2008-12-08 2014-01-16 Compugen Ltd. TMEM154 polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
NZ594343A (en) 2009-03-25 2013-10-25 Genentech Inc Novel anti-alpha5beta1 antibodies and uses thereof
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
DK3342786T3 (en) 2010-01-29 2021-09-27 Chugai Pharmaceutical Co Ltd Anti-dll3-antistof
MX2012009215A (es) 2010-02-23 2012-11-23 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores.
KR101738203B1 (ko) 2010-04-15 2017-05-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨주게이트
CA3220104A1 (fr) 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugues modifies par la cysteine
US20120121615A1 (en) 2010-11-17 2012-05-17 Flygare John A Alaninyl maytansinol antibody conjugates
JP5987053B2 (ja) 2011-05-12 2016-09-06 ジェネンテック， インコーポレイテッド フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングｌｃ−ｍｓ／ｍｓ法
EP2750713B1 (fr) 2011-10-14 2015-09-16 Spirogen Sàrl Pyrrolobenzodiazépines et conjugués associés
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
SI2814842T1 (sl) 2012-02-15 2018-10-30 Novo Nordisk A/S Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
PT2814844T (pt) 2012-02-15 2017-09-18 Novo Nordisk As Anticorpos que se ligam e bloqueiam recetor de acionamento expresso em células mieloides-1 (trem-1)
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
WO2014022679A2 (fr) 2012-08-02 2014-02-06 Genentech, Inc. Anticorps et immunoconjugués anti-etbr
EP2879711A4 (fr) 2012-08-02 2016-03-16 Genentech Inc Anticorps et immunoconjugués anti-etbr
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
AU2013328625B2 (en) 2012-10-12 2016-12-15 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
SI2906253T1 (sl) 2012-10-12 2018-11-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin-protitelo proti PSMA
HUE042731T2 (hu) 2012-10-12 2019-07-29 Adc Therapeutics Sa Pirrolobenzodiazepin-antitest konjugátumok
HUE045435T2 (hu) 2012-10-12 2019-12-30 Medimmune Ltd Pirrolobenzodiazepinek és konjugátumaik
BR112015008238A2 (pt) 2012-10-12 2017-11-28 Adc Therapeutics Sarl conjugados de pirrolbenzodiazepina-anticorpo anti-cd22
JP6307519B2 (ja) 2012-12-21 2018-04-04 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピンおよびその結合体
EA032986B1 (ru) 2012-12-21 2019-08-30 Медимьюн Лимитед Пирролобензодиазепины
JP6340019B2 (ja) 2013-03-13 2018-06-06 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
CA2905181C (fr) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee
EA027910B1 (ru) 2013-03-13 2017-09-29 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
PL2970473T3 (pl) 2013-03-14 2018-01-31 Bristol Myers Squibb Co Kombinacja agonisty dr5 i antagonisty anty-pd-1 oraz metody stosowania
MX2016001862A (es) 2013-08-12 2016-08-03 Genentech Inc Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo[e]indol, y metodos de uso y tratamiento.
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
WO2015052534A1 (fr) 2013-10-11 2015-04-16 Spirogen Sàrl Conjugués anticorps-pyrrolobenzodiazépine
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
JP6980384B2 (ja) 2013-12-16 2021-12-15 ジェネンテック， インコーポレイテッド １−（クロロメチル）−２，３−ジヒドロ−１ｈ−ベンゾ［ｅ］インドール二量体抗体−薬物コンジュゲート化合物、並びに使用及び処置の方法
EP3082875B1 (fr) 2013-12-16 2020-11-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
RU2689388C1 (ru) 2013-12-16 2019-05-28 Дженентек, Инк. Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
MY178347A (en) 2014-07-17 2020-10-08 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3191134B1 (fr) 2014-09-12 2019-11-20 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
CA2957354A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Anticorps et conjugues modifies genetiquement avec de la cysteine
MX2017003523A (es) 2014-09-17 2017-11-08 Genentech Inc Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas.
CN107148285B (zh) 2014-11-25 2022-01-04 Adc治疗股份有限公司 吡咯并苯并二氮杂䓬-抗体缀合物
EP3226909A1 (fr) 2014-12-03 2017-10-11 Genentech, Inc. Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
MA45326A (fr) 2015-10-20 2018-08-29 Genentech Inc Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP6943872B2 (ja) 2016-03-25 2021-10-06 ジェネンテック， インコーポレイテッド 多重全抗体及び抗体複合体化薬物定量化アッセイ
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
EP3464280B1 (fr) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
JP6671555B2 (ja) 2017-02-08 2020-03-25 アーデーセー セラピューティクス ソシエテ アノニム ピロロベンゾジアゼピン抗体複合体
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
AU2018255876B2 (en) 2017-04-18 2020-04-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
AU2018253948A1 (en) 2017-04-20 2019-09-19 Adc Therapeutics Sa Combination therapy with an anti-AXL Antibody-Drug Conjugate
MX2019015042A (es) 2017-06-14 2020-08-06 Adc Therapeutics Sa Regimen de dosificacion.
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
CN111788208B (zh) 2017-09-20 2023-11-24 Ph制药有限公司 泰兰他汀类似物
WO2019131988A1 (fr) 2017-12-28 2019-07-04 Chugai Seiyaku Kabushiki Kaisha Agent thérapeutique induisant une cytotoxicité
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
US11155618B2 (en) 2018-04-02 2021-10-26 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
JP2022505450A (ja) 2018-10-24 2022-01-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト コンジュゲート化された化学的分解誘導物質および使用方法
CN113227119A (zh) 2018-12-10 2021-08-06 基因泰克公司 用于与含Fc的蛋白质进行位点特异性缀合的光交联肽
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
WO2021200898A1 (fr) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Molécules multispécifiques de liaison à l'antigène ciblant dll3 et leurs utilisations
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN114113603B (zh) * 2021-06-30 2023-11-17 四川大学华西医院 Cytl1作为胃癌预后标志物的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression
WO2000028090A2 (fr) * 1998-11-12 2000-05-18 Nyxis, Inc. Essais diagnostiques du cancer
US6426186B1 (en) * 2000-01-18 2002-07-30 Incyte Genomics, Inc Bone remodeling genes

Also Published As

Publication number Publication date
AU2002330039A1 (en) 2003-04-01
EP1434881A2 (fr) 2004-07-07
JP2005518782A (ja) 2005-06-30
EP1434881A4 (fr) 2005-10-26
WO2003025138A2 (fr) 2003-03-27
WO2003025138A3 (fr) 2003-05-08

Similar Documents

Publication Publication Date Title
CA2459219A1 (fr) Procedes de diagnostic du cancer, compositions et procedes de criblage de modulateurs du cancer
US7736853B2 (en) Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer
US7435589B2 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2451465A1 (fr) Procedes de diagnostic du cancer ovarien, compositions et procedes de criblage de modulateurs du cancer ovarien
CA2453098A1 (fr) Procede de diagnostic du cancer de la vessie, compositions et procedes de criblage de modulateurs du cancer de la vessie
US20040029114A1 (en) Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20030235820A1 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
US20050181375A1 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
CA2440703A1 (fr) Procedes de diagnostic du cancer du sein, compositions et procedes de criblage de modulateurs du cancer du sein
CA2444691A1 (fr) Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon
CA2425569A1 (fr) Procedes de diagnostic du cancer de la prostate, compositions et procedes de criblage de modulateurs du cancer de la prostate
CA2438030A1 (fr) Methode de diagnostic de l'angiogenese, preparations et methodes d'identification par criblage de modulateurs de l'angiogenese
WO2004048938A2 (fr) Procedes de detection du sarcome des tissus mous, compositions et procedes de criblage des modulateurs du sarcome des tissus mous
AU2008229749A1 (en) Novel compositions and methods for cancer
US20030228570A1 (en) Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
AU2009202600A1 (en) Novel compositions and methods for cancer
AU2002367390A1 (en) Novel compositions and methods for cancer
CA2467433A1 (fr) Methodes de diagnostic du cancer, compositions et methodes de criblage des modulateurs du cancer
AU2003224641A1 (en) Novel compositions and methods for cancer
CA2479721A1 (fr) Compositions et procedes utilisables, pour le cancer, en association avec une expression modifiee du recepteur de la prolactine (prlr)
EP1847620A2 (fr) Procédé pour le diagnostic du cancer de la prostate, compositions et procédés pour le dépistage de modulateurs du cancer de la prostate
AU2003218331B2 (en) Novel compositions and methods in cancer associated with altered expression of PRDM 11
CA2479731A1 (fr) Nouvelles compositions et methodes de traitement d'un cancer associees a l'expression alteree de tbx21
EP1490690A2 (fr) Nouvelles compositions et procedes utilises dans le traitement du cancer et associes a l'expression modifiee de mcm3ap
AU2003225750A1 (en) Novel compositions and methods in cancer associated with altered expression of kcnj9

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued